MedTrace Logo

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

NCT05135364 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-11-26

No results posted yet for this study

Summary

The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research. In this single-arm, open-label, prospective study, for those patients with unresectable primary HCC, in the case of failure of TACE treatment, the combination of HAIC, TKI and immunotherapy is expected to bring new breakthroughs.

Conditions

Interventions

DRUG

Camrelizumab

Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks

DRUG

HAIC

A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks

DRUG

TKI

Lenvatinib or Regorafenib

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Yue Han

    lead OTHER

Principal Investigators

  • yue Han, phD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2022-10-05
Completion
2024-12-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135364 on ClinicalTrials.gov